Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.63 |
| ▸ | RXRG | P48443 | 8/20 | 0.63 |
| ▸ | RXRB | P28702 | 7/20 | 0.63 |
| ▸ | PPARD | Q03181 | 8/20 | 0.61 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.58 |
| ▸ | KIF11 | P52732 | 1/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491483 | 0.94 | RXRA (0.71) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL491624 | 0.89 | RXRA (0.65) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL2272003 | 0.82 | RXRA (0.77) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL491523 | 0.81 | PPARD (0.57) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL11960675 | 0.81 | PPARD (0.60) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL3574038 | 0.81 | PPARD (0.67) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL6267349 | 0.80 | PSEN1 (0.64) | RXRARXRGRXRBPPARDPSEN1 | |
| SCHEMBL478042 | 0.79 | PPARD (0.65) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL9895027 | 0.78 | RXRA (0.57) | RXRARXRGRXRBPPARDPPARA | |
| SCHEMBL3573491 | 0.77 | PPARD (0.62) | RXRARXRGRXRBPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | claimed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | claimed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | claimed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | claimed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1847524-B1 | Terphenyl derivatives for treatment of Alzheimer's disease | CELLZOME LTD (GB) | 2009-10-14 | — | — | EP | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | BACE1, BACE2, APP | RXRA 1179/4885RXRG 1200/4885RXRB 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.